Imaging giant GE Healthcare announced this week that it’s teaming with biotech firm Theragnostics in a bid to improve prostate cancer treatment.
The two said Wednesday, Oct. 9, that they’ll work in tandem to produce a prostate-specific membrane antigen PET/CT imaging agent. Theragnostics will champion development of the tracer—which they’re calling GalliProst—while GE Healthcare will handle preapproval processes and commercial distribution.
Typically, prostate cancer is first detected through a blood test or biopsy and then confirmed using PET/CT imaging to chart a treatment course. GalliProst uses heatmap-style imaging to pinpoint the exact location of the tumor. Providers changed treatment plans for about one-third of newly diagnosed prostate cancer patients when deploying the technology, Theragnostics found in a clinical study.
"We are excited to partner with Theragnostics on GalliProst to give vital insights into prostate cancer," Sanka Thiru, a global product leader in molecular imaging oncology for GE Healthcare, said in a statement. "We believe that this partnership enables both parties to leverage each other's key areas of expertise in order to accelerate the development of GalliProst and ultimately improve patient care."